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Abstract
Background: The prognostic significance of germline
mutations in BRCA1 and BRCA2 in women with breast cancer
remains unclear. A combined analysis was performed to
address this uncertainty.
Methods: Two retrospective cohorts of Ashkenazi Jewish
women undergoing breast-conserving treatment for invasive
cancer between 1980 and 1995 (n=584) were established.
Archived tissue blocks were used as the source of DNA for
Ashkenazi Jewish BRCA1/BRCA2 founder mutation analysis.
Paraffin-embedded tissue and follow-up information was
available for 505 women.
Results: Genotyping was successful in 496 women, of whom
56 (11.3%) were found to carry a BRCA1/BRCA2  founder
mutation. After a median follow-up period of 116 months,
breast cancer specific survival was worse in women with
BRCA1  mutations than in those without (62% at 10 years
versus 86%; P<0.0001), but not in women with the BRCA2
mutation (84% versus 86% at 10 years; P=0.76). Germline
BRCA1 mutations were an independent predictor of breast
cancer mortality in multivariate analysis (hazard ratio 2.4, 95%
confidence interval 1.2–4.8; P=0.01).  BRCA1 status
predicted breast cancer mortality only among women who did
not receive chemotherapy (hazard ratio 4.8, 95% confidence
interval 2.0–11.7; P=0.001). The risk for metachronous
ipsilateral cancer was not greater in women with germline
BRCA1/BRCA2 founder mutations than in those without
mutations (P=0.68).
Conclusion: BRCA1 mutations, but not BRCA2 mutations, are
associated with reduced survival in Ashkenazi women
undergoing breast-conserving treatment for invasive breast
cancer, but the poor prognosis associated with germline
BRCA1 mutations is mitigated by adjuvant chemotherapy. The
risk for metachronous ipsilateral disease does not appear to be
increased for either BRCA1 or BRCA2 mutation carriers, at
least up to 10 years of follow up.
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Introduction
The major breast cancer predisposing genes BRCA1 and
BRCA2 were identified in 1994 and 1995, respectively
[1,2]. Unfortunately, the optimal clinical approach to
women who develop hereditary breast cancer remains
incompletely defined. Studies of the outcomes of women
with BRCA1/BRCA2-related cancer have yielded conflict-
ing results. Several reports suggested that women with
germline mutations in BRCA1 are more likely to die from
their disease than are women with sporadic breast cancer
[3–6]. However, other studies did not confirm these
observations [7,8]. Fewer studies have focused on
BRCA2-related breast cancer [9,10].
Certain unique barriers have impeded the analysis of
germline BRCA1/BRCA2 status as a prognostic factor.
Because informed consent is required for genetic testing,
and individuals may decline such testing for a variety of
reasons, it has been difficult to develop prospective
cohorts for outcome studies. On the other hand, testing
generally requires the provision of a blood sample, which
may introduce a survival bias in the conduct of retrospec-
tive studies. Both of these potential selection biases may
be avoided through the use of a retrospective design in
which BRCA1/BRCA2 mutations are sought in archival
tissue from women who have undergone treatment for
cancer, and in whom the clinical outcomes are known.
Genetic testing is performed on anonymized tissue speci-
mens, and comparisons are made between the women
who do and those who do not have mutations. This design
presupposes that the BRCA1/BRCA2 mutation spectrum
in the study group is limited and predefined. This is the
case for women of Ashkenazi Jewish descent, because
two specific mutations of BRCA1 (185delAG and
5382insC) and one mutation of BRCA2 (6174delT) con-
stitute the great majority of mutations identified in this pop-
ulation, and these are easily detectable in
paraffin-embedded material [11–14]. The present study
employed this retrospective, anonymized design to
examine the outcomes of Ashkenazi women with invasive
breast cancer undergoing breast-conserving therapy
(BCT) at two institutions in the USA and Canada.
Methods
Patients
Patients from Memorial Sloan-Kettering Cancer Center
(MSKCC) were identified as previously described [15].
Briefly, clinical databases from the Departments of Pathol-
ogy, Surgery, and Radiation Therapy were reviewed to
identify women who underwent BCT (wide local excision
and radiation, with or without axillary node dissection)
between 1 January 1980 and 31 December 1990. Hospi-
tal registration databases were then cross-referenced to
identify women expressing Jewish religious preference. Of
the 393 Jewish women undergoing BCT, paraffin-embed-
ded tissue and follow-up information was available for
314 women. Information on tumor grade was not available.
The combined impact of germline mutations in
BRCA1/BRCA2 on prognosis in this group of women
was reported in a previous publication [15]. For the
present study the clinical database was extended and
additional analyses were performed evaluating the prog-
nostic impact of interactions between germline status,
hormone receptor status, and adjuvant treatment with
either tamoxifen or chemotherapy. The clinical impact of
germline mutations in BRCA1 and BRCA2 were consid-
ered separately.
Ashkenazi Jewish women diagnosed with invasive non-
metastatic breast cancer at age 65 years or less, who
were treated at Sir Mortimer B. Davis-Jewish General Hos-
pital (SMBD-JGH) between 1 January 1980 and 1 Novem-
ber 1995, were identified from the Medical Records
Department. Of 292 women identified, 225 underwent
breast-conserving surgery. Of these 225 women, 34 did
not receive radiation and are excluded from further consid-
eration. Paraffin-embedded tissue and follow-up informa-
tion was available for the remaining 191 women, who
were included in the analysis. Results relating to germline
mutations in BRCA1 for the entire dataset were recently
reported [16]. The study was focused on those receiving
BCT to harmonize the ascertainment criteria between the
two centers and to focus on ipsilateral cancer recurrence.
The two studies were combined to increase the sample
size and thereby the power to observe the separate
effects of mutations in BRCA1 and BRCA2, which was
not previously possible with either dataset alone.
Data collection
Study procedures at each institution were approved by
the local institutional review board. For each subject,
paraffin-embedded material was retrieved from hospital
tissue banks and clinical records were reviewed. In order
to comply with guidelines regarding the conduct of
genetic research on stored tissue samples, only a limited
amount of clinical data was extracted from the medical
record, including age at diagnosis (<50 or ≥50 years),
tumor size (≤2cm or >2cm), lymph node involvement
(present or absent), hormone receptor status (if available),
and adjuvant treatment with chemotherapy or tamoxifen.
Time to development of local or distant recurrence was
recorded, as was the time to development of contralateral
breast cancer, if any. Clinical follow-up information was
obtained by chart review, tumor registry query, and
contact with the treating physician. The tissue specimen
and clinical data for each subject were associated through
a unique study identifier. At MSKCC, the link between
study identifier and patient identifying information was irre-
trievably destroyed before genetic analysis was per-
formed. At the SMBD-JGH, the mutation results were
anonymized and separated from any personal identifiers in
a manner approved by the local institutional review board.Breast Cancer Research    Vol 6 No 1 Robson et al.
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Genetic analysis
Analysis of the paraffin-embedded specimens was per-
formed as previously described [3,15]. Briefly, paraffin
sections were obtained from the retrieved tissue blocks
and genomic DNA was isolated by standard protocols. At
MSKCC normal lymph node was preferentially examined,
whereas at SMBD-JGH tumor tissue was studied. All
specimens were analyzed by PCR amplification of the
regions surrounding the Ashkenazi founder mutations
185delAG and 5382insC in BRCA1 and 6174delT in
BRCA2. Radiolabeled PCR products were visualized by
denaturing PAGE followed by autoradiography. The
detection of characteristic variant bands indicated the
presence of the mutation being studied. Variant bands
were confirmed by direct sequencing or by an indepen-
dent PCR amplification of the corresponding DNA sample
and repeat analysis. There were no discordant results
upon repeat analysis.
DNA samples from nine patients failed to yield PCR prod-
ucts despite repeat analysis. Therefore, the final study
group consisted of 496 women. There were 24 women
who underwent contralateral BCT for metachronous
breast cancer during the period of the study. Thus, for the
purposes of determining the rate of metachronous ipsilat-
eral cancer, there were 520 breasts at risk in the dataset.
Statistical analyses
Clinical characteristics of women with and without
germline  BRCA1/BRCA2 founder mutations were com-
pared using a χ2 test. For the survival analyses, breast
cancer specific mortality was chosen as the main end-
point for the study in order to avoid possible confounding
by death due to other causes, such as malignancies of
other anatomic sites. Overall survival, defined as the time
from diagnosis to death from any cause, was evaluated as
a secondary end-point. All ipsilateral breast cancer events
were considered in the calculation of the cumulative inci-
dence of metachronous ipsilateral breast cancer, because
the retrospective design of this study did not allow reliable
discrimination between true recurrences and separate
metachronous primaries. All contralateral breast cancer
diagnoses were considered new primary lesions for the
purposes of calculating the cumulative incidence of con-
tralateral breast cancer. Women who had undergone con-
tralateral mastectomy before the breast cancer diagnosis
for which they underwent breast conservation (n=7) were
excluded from the analysis of this end-point.
Patients were censored if they had not experienced the
end-point of interest at the time of last follow up.
Kaplan–Meier estimates of breast cancer specific survival
time were compared using the log-rank test. A Cox pro-
portional hazards model was used to estimate the hazard
ratios (HRs) for breast cancer specific survival time under
a multivariate model. All other end-points were analyzed
after accounting for death due to causes other than breast
cancer as a competing risk. The cumulative incidences of
the end-points in women with and without mutations were
compared with a χ2 test fit using the method of Gray [17].
Pvalues comparing the overall curves corresponding to
the end-point of interest are provided for these univariate
comparisons. The cumulative incidences of death due to
breast cancer and due to causes other than breast cancer
are both calculated in the same analysis, and shown in
separate figures. Multivariate proportional hazards models
accounting for non-breast-cancer death as a competing
risk were fitted using the method of Fine and Gray [18]. All
Pvalues were calculated using two-sided tests.
Results
Mutation analysis and clinical characteristics
BRCA1/BRCA2 mutations were identified in 56 (11.3%)
of 496 patients (42 BRCA1  [32 women carried the
185delAG and 10 carried the 5382insC mutation],
13 BRCA2  [all 6174delT], and one both BRCA1 and
BRCA2 [185delAG and 6174delT]). The clinical charac-
teristics of women with BRCA1, BRCA2, and no germline
BRCA1/BRCA2 mutations are presented in Table 1.
Women with germline BRCA1 mutations were signifi-
cantly more likely than women without these specific
mutations to be diagnosed before the age of 50 years, to
be diagnosed with estrogen receptor negative tumors,
and to have received adjuvant chemotherapy. BRCA1
mutation carriers were significantly less likely than noncar-
riers to have received tamoxifen (Table 1). In women with
BRCA1 mutations, neither tumor size nor axillary nodal
involvement differed significantly from noncarriers. Among
those for whom data were available, BRCA2 mutation car-
riers were more likely than BRCA1 carriers to have estro-
gen receptor positive tumours (odds ratio 10.5;
P=0.004) and to have received adjuvant tamoxifen (odds
ratio 5.4; P=0.02). For no other variable was the distribu-
tion significantly different between BRCA2 mutation carri-
ers and either BRCA1 carriers or noncarriers.
Breast cancer specific survival
The median follow-up period for surviving women was
116 months. There were 79 women who died from breast
cancer, 34 who died from causes other than breast
cancer, and one whose cause of death was unknown.
There were 18 deaths due to breast cancer among the
57 women with BRCA1/BRCA2 mutations. Sixteen
deaths occurred among 43 BRCA1 carriers and two
among 14 BRCA2 carriers, and there were 61 breast
cancer related deaths among the 439 women who did not
have a detectable BRCA1/BRCA2 mutation. At 10 years,
the cumulative incidence of death due to breast cancer
among  BRCA1/BRCA2 mutation carriers was 33%, as
compared with 14% among noncarriers (P=0.0002).
However, the negative impact of mutation status was not
evenly distributed among BRCA1/BRCA2 carriers,because the probability of death due to breast cancer
among  BRCA1 mutation carriers was 38% at 10 years
(P<0.0001, versus noncarriers; Fig.1 and Table 2) and
15.5% among women with the BRCA2 founder mutation
(P=0.76 versus non-carriers; Table 2). There was no dif-
ference between women with and those without
BRCA1/BRCA2 mutations with respect to the probability
of death due to causes other than breast cancer
(P=0.38; Fig.2).
In univariate analyses, age under 50 years at initial diagno-
sis, presence of a BRCA1 mutation, primary tumor size
greater than 2cm, estrogen receptor negativity, axillary
nodal involvement, and receipt of adjuvant chemotherapy
were all significantly associated with poorer breast cancer
specific survival (Table 2). Adjuvant treatment was not ran-
domly assigned, and therefore the association between
administration of chemotherapy and a poor outcome
(P<0.0001) is probably accounted for by the fact that
women who were given chemotherapy had a higher a
priori probability of death than did those not receiving
adjuvant chemotherapy. For this reason, use of
chemotherapy was not included as a variable in the final
multivariate model. In a multivariate competing risk analysis
of breast cancer specific survival, we included only those
variables that were significant in the univariate analysis.
The final, most parsimonious model is shown in Table 3.
BRCA1 mutation status retained independent prognostic
significance (HR 2.39, 95% confidence interval [CI]
1.20–4.75; P=0.01), along with tumor size greater than
2cm (HR 2.19, 95% CI 1.30–3.67; P=0.003) and axillary
nodal involvement (HR 1.78, 95% CI 1.07–2.96;
P=0.03). Women diagnosed after the age of 50 years
were less likely to die from breast cancer than were
Available online http://breast-cancer-research.com/content/6/1/R8
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Table 1
Clinical characteristics of women with and without BRCA founder mutations
No BRCA founder BRCA1 founder P (BRCA1 versus no BRCA2 founder P (BRCA2 versus
Variable mutation (n=440) mutation (n=43)† founder mutation)* mutation (n=14)† no founder mutation)*
Age at diagnosis (years)
< 50 135 (31%) 30 (70%) < 0.0001 4 (29%) NS
≥ 50 305 (69%) 13 (30%) 10 (71%)
Tumor size
T1 324 (74%) 29 (67%) NS 8 (57%) NS
T2 97 (22%) 11 (26%) 4 (29%)
Unknown 19 (4%) 3 (7%) 2 (14%)
Nodal involvement
Present 149 (34%) 18 (42%) NS 6 (43%) NS
Absent 262 (60%) 23 (53%) 6 (43%)
Unknown 29 (6%) 2 (5%) 2 (14%)
Estrogen receptor
Positive 197 (45%) 6 (14%) < 0.0001 7 (50%) NS
Negative 98 (22%) 27 (63%) 3 (21%)
Unknown 145 (33%) 10 (23%) 4 (29%)
Chemotherapy
Yes 156 (35%) 24 (56%) 0.02 7 (50%) NS
No 257 (58%) 17 (40%) 7 (50%)
Unknown 27 (10%) 2 (4%) 0 (0%)
Tamoxifen
Yes 190 (43%) 10 (23%) 0.01 9 (64%) NS
No 203 (46%) 30 (70%) 5 (36%)
Unknown 47 (11%) 3 (7%) 0 (0%)
*Cases in which the characteristic of interest is unknown are not included in the comparisons. †Woman with both BRCA1 and BRCA2 founder
mutations are included in both groups, hence the total number women listed here is 497.younger women (HR 0.55, 95% CI 0.33–0.92; P=0.02;
Table 3). The models were essentially unchanged when
overall survival was the end-point. The presence of the
BRCA2 mutation was not a significant prognostic factor in
either univariate (Table 2) or multivariate analysis (data not
shown).
Effect of adjuvant treatment
Of the 468 women in the study for whom information
regarding adjuvant chemotherapy was available, 187
received chemotherapy and 281 did not. In univariate
analysis the presence of a germline BRCA1 mutation was
significantly associated with a worse breast cancer spe-
cific survival both among those women who received
chemotherapy (10-year breast cancer mortality 41% in
carriers versus 24% in noncarriers; P=0.04) and among
those who did not (10-year breast cancer mortality 24% in
carriers versus 9.6% in noncarriers; P=0.008). The pres-
ence of a germline BRCA1 mutation remained an inde-
pendent predictor of breast cancer mortality in multivariate
Breast Cancer Research    Vol 6 No 1 Robson et al.
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Figure 1
Cumulative incidence of death due to breast cancer among women
with (····) and those without (––) germline BRCA1 mutations
(P<0.0001).
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Table 2
Univariate analysis of factors influencing breast cancer
specific survival
Variable n Breast cancer deaths (n) P
BRCA mutation
Any 56 18 0.0002
None 439 61
BRCA1 mutation
Mutation present 43 16 < 0.0001
Mutation absent 439 61
BRCA2 mutation
Mutation present 14 2 0.76
Mutation absent 439 61
Tumor size
≤ 2 cm 360 41 < 0.0001
> 2 cm 111 31
Axillary node
Negative 290 31 < 0.0001
Positive 172 44
Estrogen receptor
Positive 210 28 0.01
Negative 127 31
Age at diagnosis (years)
< 50 169 42 < 0.0001
≥ 50 326 37
Chemotherapy
Yes 187 48 < 0.0001
No 279 30
Tamoxifen
Yes 208 28 0.14
No 237 47
Figure 2
Cumulative incidence of death due to causes other than breast cancer
in women with (––) and in those without (–·–) germline BRCA
mutations (P=0.38).
N at risk
Year 1 Year 3 Year 5 Year 10 Year 12 Year 15
Mutation present 55 46 40 12 7 2
Mutation absent 435 416 382 182 101 19
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0analysis of the group of women who did not receive
chemotherapy (HR 4.8, 95% CI 2.0–11.7; P=0.001), but
not in those women who did receive adjuvant chemother-
apy (HR 1.5, 95% CI 0.66–3.49; P=0.33). There were
208 women who received adjuvant tamoxifen and 237
who did not. Tamoxifen usage was not a significant predic-
tor of outcome in univariate analysis. However, in multivari-
ate analysis, among those not receiving tamoxifen, the
presence of a germline BRCA1 mutation was significantly
associated with breast cancer specific survival (HR 3.5,
95% CI 1.7–7.2; P=0.001). By contrast, BRCA1 muta-
tions had no prognostic value in those who did receive
tamoxifen (HR 0.5, 95% CI 0.05–5.0; P=0.55).
Ipsilateral and contralateral breast cancer
A total of 496 patients in the present study underwent
BCT for 520 invasive breast cancers. There was no signifi-
cant difference between women with and those without
BRCA1/BRCA2 mutations in the risk for metachronous
ipsilateral breast cancer at 10 years (12% in women with
mutations versus 8% in women without; P=0.68; Fig.3).
Age under 50 years at initial diagnosis was the only signifi-
cant predictor of metachronous ipsilateral disease
(P=0.002). Women with mutations were significantly
more likely to develop contralateral breast cancer at
10 years (27% in women with mutations versus 8% in
women without; P<0.0001, based on a competing cause
analysis; Fig.4). The risk for contralateral cancer was
similar in women with BRCA1 mutations (27% at
10 years) and in those with the BRCA2 mutation (32% at
10 years). In univariate analyses, which were adjusted for
death from competing causes, women not using tamoxifen
experienced a higher incidence of ipsilateral breast cancer
(HR 1.97, 95% CI 1.01–3.86; P=0.05). Those not using
tamoxifen also had a marginally, nonsignificantly higher
incidence of contralateral breast cancer (HR 1.26, 95% CI
0.71–2.25; P=0.48). Chemotherapy did not have a signif-
icant effect on either ipsilateral (P=0.16) or contralateral
(P=0.36) breast cancer incidence. In an analysis
restricted to mutation carriers, the contralateral breast
cancer risk was lower in BRCA1/BRCA2 mutation carri-
ers receiving tamoxifen than in those not receiving tamox-
ifen, although this did not reach statistical significance
(risk ratio 0.47, 95% CI 0.14–1.59; P=0.23). The effect
of tamoxifen on contralateral breast cancer risk was not
significantly greater in women with a BRCA2 mutation
than in women with BRCA1 mutations, although this
analysis was limited by the small numbers of women in
each group.
Discussion
Although  BRCA1 and  BRCA2  were identified in 1994
and 1995, the influence of germline BRCA1/BRCA2
mutations on the outcome of women with breast cancer
has remained undefined. Several retrospective studies of
affected mutation carriers identified by familial cancer risk
clinics failed to demonstrate any differences in survival
when women with mutations were compared with various
control groups (for reviews [19,20]). However, because
only women who survived their breast cancer were able to
undergo genetic testing and be identified as mutation car-
Available online http://breast-cancer-research.com/content/6/1/R8
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Figure 3
Cumulative incidence of metachronous ipsilateral breast cancer in
women with (––) and in those without (––) germline BRCA mutations
(P=0.68).
Breasts at risk
Year 1 Year 3 Year 5 Year 10 Year 12 Year 15
Mutation present 61 48 39 10 5 5
Mutation absent 453 417 375 172 94 94
Time (years)
05 10 15
0.0
0.2
0.4
0.6
0.8
1.0
Cumulative
Incidence
Table 3
Final multivariate model of breast cancer specific survival
Deaths due
to breast Hazard ratio
Variable n cancer (n) (95% CI) P
BRCA1 mutation
No mutation 397 52 1.00 0.01
BRCA1 37 14 2.39 (1.20–4.75)
Tumor size
< 2 cm 333 39 1.00 0.003
≥ 2 cm 101 27 2.19 (1.30–3.67)
Axillary node
Negative 280 31 1.00 0.03
Positive 154 35 1.78 (1.07–2.96)
Age (years)
< 50 146 34 1.00 0.02
≥ 50 288 32 0.55 (0.33–0.92)
CI, confidence intervalriers in these prevalent series, a survival bias may have
prevented the detection of a negative impact of
BRCA1/BRCA2 mutations on outcome. The anonymized
design of the current retrospective study circumvented
this potential bias by ensuring that all patients within the
study group were genotyped, without regard for vital
status.
In the present study, women undergoing BCT for early
stage invasive breast cancer demonstrated significantly
shorter breast cancer specific and overall survival if they
carried a germline BRCA1 mutation but not a BRCA2
mutation. This suggests that the clinical outcome of
women with germline mutations may vary depending on
which gene is mutated, and even possibly on the position
of the mutation within a particular gene. However, the
present study, examining the consequences of an inten-
tionally restricted set of mutations in a limited sample,
cannot definitively resolve this question. Larger studies,
preferably of prospectively ascertained incident cohorts,
are necessary.
The adverse prognosis conferred by a BRCA1 mutation
was not attributable to differences in tumor size or axillary
nodal status, which indicates that the impact of germline
status on clinical outcome is not the result of an associa-
tion with advanced stage at diagnosis. Several studies
have demonstrated that breast cancers arising in women
with  BRCA1/BRCA2 mutations, particularly those in
BRCA1, frequently manifest adverse pathologic and bio-
logic features, such as high histologic grade, hormone
receptor negativity, p53 mutation, aneuploidy, and high
S-phase fraction [19]. Studies conducted in sporadic
breast cancer have previously demonstrated the negative
prognostic significance of each of these factors. Whether
the prognostic significance of BRCA1/BRCA2 status is
completely independent of all of these other parameters
cannot be resolved by the present study. BRCA1-related
breast cancers in this series, as in others, were signifi-
cantly more likely to be estrogen receptor negative than
were cancers not associated with BRCA1 mutations, and
estrogen receptor status was associated with breast
cancer mortality in univariate analysis. However, germline
status remained a significant prognostic indicator in the
multivariate model, indicating that the adverse effect of
mutation status on outcome is independent of the associa-
tion with estrogen receptor negative phenotype. The
robustness of this observation is limited to some degree
by the fact that receptor status was unknown for a signifi-
cant proportion of patients, in part because some of these
cases were diagnosed before routine receptor testing and
in part because the small size of some tumors prevented
receptor determination using the dextran-coated charcoal
method in use at the time.
The design of the present study precluded a separate
analysis of the role of grade in determining outcome in
BRCA1 carriers. However, it is known that the majority of
BRCA1-related breast cancers are high grade, infiltrating
ductal breast cancers [21]. It would not significantly
change the conclusions of this study if it could be demon-
strated that the independent negative impact observed is
attributable to the ‘downstream’ phenotypic conse-
quences of the presence of a BRCA1 mutation.
Some preclinical studies have demonstrated that mouse
embryonic cells lacking functional Brca1 protein are sensi-
tive to specific chemotherapeutic agents such as cisplat-
inum and mitomycin C [22,23], and similar results have
been seen in human breast cancer cells null for BRCA1
protein [24]. These observations have raised the possibil-
ity that human BRCA1-associated breast cancers might
also be differentially sensitive to chemotherapy. The
current analysis is consistent with this hypothesis,
because the negative prognostic influence of a germline
BRCA1  mutation appeared to be reduced in women
receiving adjuvant chemotherapy, and, in fact, lost inde-
pendent statistical significance in this group. Furthermore,
standard chemotherapy regimens do not include mito-
mycin-C or cisplatinum, and it remains possible that
BRCA1-associated breast cancers may be even more
sensitive to these agents. However, the design of the
present study is such that these observations must be
considered hypothesis generating. Further exploration
should take place within the context of prospective trials.
Breast Cancer Research    Vol 6 No 1 Robson et al.
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Figure 4
Cumulative incidence of metachronous contralateral breast cancer in
women with (····) and in those without (––) germline BRCA mutations
(P<0.0001).
N at risk
Year 1 Year 3 Year 5 Year 10 Year 12 Year 15
Mutation present 49 40 33 9 5 5
Mutation absent 424 401 365 167 88 88
Time (years)
05 1 0 15
0.0
0.2
0.4
0.6
0.8
1.0
Cumulative
IncidenceIn the present study, women with germline mutations
experienced a risk for metachronous ipsilateral breast
cancer that was not significantly different from that in
women without mutations. Several studies have described
the incidence of subsequent ipsilateral disease in women
with  BRCA1/BRCA2 mutations undergoing BCT
[7,8,15,25,26]. In these series, ipsilateral tumor recur-
rence rates ranged from 1% to 20% at 5 years, which are
in the range previously reported in series of young women
undergoing BCT. A recent analysis of mutation carriers
who had survived a mean of 14 years after their breast
cancer diagnosis [27] indicated a 49% estimated risk for
ipsilateral cancer after 10 years of follow up. However,
studies such as this, which analyze prevalent groups of
long-term survivors, may overestimate the risk that a newly
diagnosed woman with a BRCA1/BRCA2 mutation will
suffer an ipsilateral breast cancer, because a significant
fraction of newly diagnosed women will unfortunately die
from their breast cancer and thus will not have lived long
enough to develop a second ipsilateral tumor. Thus, ipsi-
lateral cancer estimates derived from such studies may be
misleading for newly diagnosed women attempting to
make the difficult choice between breast conservation and
bilateral mastectomy.
Taken together, the results of the available series suggest,
at least up to 10 years of follow up, that women with
BRCA1/BRCA2 germline mutations have a risk for ipsilat-
eral recurrence that is similar to that of other young
women. Studies based on series of prevalent cases
[8,26,27] suggest, however, that women who are long-
term survivors may have an increased risk of new second
primary malignancies within the treated breast. This inter-
pretation is supported by a further analysis of cases
reported by Haffty and colleagues [28], in which all eight
patients with deleterious BRCA1/BRCA2 mutations had
new primary ipsilateral breast cancer, whereas patients
without deleterious mutations had both true recurrences
and new primary breast cancers (P=0.06). The cancers
occurring in BRCA1/BRCA2 carriers occurred at a mean
time interval of 9.6 years following the initial diagnosis.
Women with BRCA1/BRCA2 mutations are at substantial
increased risk for metachronous contralateral breast
cancer throughout the follow-up period. Although this
increased contralateral risk could reflect an increased sen-
sitivity to radiation-induced malignancies initiated by
scatter from adjuvant radiotherapy, the contralateral inci-
dence rate is similar to that observed in affected mutation
carriers after mastectomy [29] and in prospectively fol-
lowed cohorts of heterozygotes [30,31], which suggests
that the observed contralateral breast cancers are most
likely the direct result of the underlying genetic predisposi-
tion. The apparent paradox of differential ipsilateral and
contralateral risk, as well as differences in estimates of
ipsilateral risk according to duration of follow up, may be
explained by a model that proposes that women present-
ing with BRCA1/BRCA2-associated breast cancer have
multiple foci within both breasts at various stages of evolu-
tion toward malignancy. These foci may be eliminated or
substantially retarded by adjuvant radiotherapy of the ini-
tially affected breast, preventing or delaying their appear-
ance as metachronous ipsilateral cancers. In the untreated
contralateral breast, however, occult lesions existing at the
time of initial diagnosis could proceed unimpeded in their
progression to malignancy, resulting in an unaltered risk
for contralateral cancer. Extending the hypothesis, the
continued presence of the genetic predisposition may
permit the process of carcinogenesis in the affected
breast to begin anew once the radiation treatment was
completed, and, after a delay, metachronous breast
cancers would begin to appear in the treated and
untreated breasts at similar rates. This hypothetical model
could be tested by careful pathologic examination of
breasts of women with BRCA1/BRCA2 mutations under-
going either therapeutic or prophylactic mastectomy to
assess the prevalence of occult premalignant and malig-
nant lesions. The results of early reports are conflicting,
but there is some evidence for an excess of premalignant
changes, particularly for BRCA2 mutation carriers
[32–34].
Nonsurgical options for breast cancer risk reduction in
women with BRCA1/BRCA2 mutations are limited. A pre-
vious case–control study [35] suggested that tamoxifen
reduced the risk for contralateral cancer by nearly 50% in
mutation carriers, but this benefit was not observed in a
prospective trial of primary prevention among unaffected
women with BRCA1 mutations [36]. In the present study,
a trend toward a reduction in contralateral breast cancer
was seen in mutation carriers who received the drug,
although this did not achieve statistical significance.
Because the number of women with mutations who
received tamoxifen was small, the present series cannot
satisfactorily address whether the benefit of tamoxifen in
reducing contralateral risk varies between women with
BRCA1 and those with BRCA2 mutations. It is of interest
that the degree of contralateral risk reduction experienced
by the mutation carriers taking tamoxifen in the study was
similar to that reported in the previous case–control study,
and there was no clear difference between the effects
observed in BRCA1  and BRCA2 mutation carriers, but
further studies of larger numbers of women are needed
before these data can be used to guide clinical practice.
Retrospective anonymized studies such as the one
reported here may be more easily performed in popula-
tions with a high prevalence of specific founder
BRCA1/BRCA2 mutations, such as the Ashkenazim. Non-
founder mutations are not identified with this design, and a
small number of individuals will thus be misclassified as
‘mutation negative’ when, in fact, they carry a unique dele-
Available online http://breast-cancer-research.com/content/6/1/R8
R15terious alteration. However, the number of such cases is
likely to be small. In a recent report of 322 Ashkenazi indi-
viduals who underwent full sequence analysis of BRCA1
and BRCA2 after negative founder mutation testing, only
six (1.9%) were found to carry a unique mutation [37].
Because women undergoing complete sequencing were
probably encouraged to do so because of a family history
of breast or ovarian cancer, the prevalence of unique
mutations is likely to be even lower in an unselected popu-
lation of breast cancer patients such as those reported in
the present study. Thus, false-negative classification is
unlikely to have significantly affected the results of this
study. Nonetheless, the results of the study may not be
applicable to all women with BRCA1/BRCA2 mutations.
The majority of mutation carriers in the study carried either
BRCA1 185delAG (32 out of 42 [76%] of all BRCA1
mutation carriers) or BRCA2 6174delT. It is possible that
other mutant alleles may confer different risks for recur-
rence.
Conclusion
This combined study demonstrates that women with spe-
cific  BRCA1/BRCA2  mutations who develop breast
cancer are at increased risk for death from their disease,
particularly if the mutation is in BRCA1. For up to 10 years
after diagnosis, the risk for metachronous ipsilateral
cancer is similar to that in women without mutations, but
the risk for contralateral disease is substantially higher.
Taken together, these findings suggest that the possibility
of  BRCA1/BRCA2-associated breast cancer should be
taken into account with other factors when making deci-
sions regarding radiotherapy and adjuvant chemotherapy,
but should not be used as a sole factor to determine the
appropriateness of BCT. Adjuvant tamoxifen should be
given when appropriate to BRCA1/BRCA2 mutation car-
riers with hormone receptor positive breast cancer, but
despite promising data, the true effectiveness of this agent
in reducing contralateral breast cancer risk in this group of
women remains uncertain.
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